The Demographic Tide: How Aging and Comorbidity are Reversing Hard-won Gains in Kidney Allograft Survival

The long-term trajectory of kidney allograft survival has occupied transplant nephrologists for decades,1 yet direct observational evidence spanning >25 y remains remarkably scarce. The study by Wiebe et al2 in this issue of Transplantation is therefore a genuinely rare contribution. By assembling 2076 consecutive kidney transplants at the University of Manitoba between 1969 and 2024, representing up to 55 y of uninterrupted follow-up, the authors provide directly observed, nonprojected outcome data that no registry study has previously achieved. The central finding is sobering while death-censored graft survival has plateaued, all-cause graft survival (ACGS) has reversed course in the modern era (2018–2024) relative to its 1998–2009 peak (P = 0.007), driven by a rising burden of death with a functioning graft, particularly from infectious causes. These findings should be interpreted within the context of large registry analyses. Specifically, Poggio et al3 used the Scientific Registry of Transplant Recipients (SRTR) to document steady improvements in the adjusted hazard of graft failure across eras in a cohort of >331 000 US patients. Manitoba’s peak median survival of 14.7 y during 1998–2009 substantially exceeded the contemporary SRTR benchmark of 11.3 y, a superiority plausibly attributable to early adoption of flow cytometric crossmatch, solid-phase donor-specific antibody screening, strict avoidance of pretransplant donor-specific antibody, and universal immunosuppression access under the Canadian health system. The subsequent decline may therefore partly reflect convergence toward national norms rather than true deterioration in care quality. The distinction matters: if convergence explains the trend, the alarm threshold is lower, but the imperative to adapt to a changing patient population is no less urgent. The demographic transformation documented here is striking. Median recipient age rose from 35 to 54 y and donor age from 28 to 45 y; the proportion of recipients aged 60 y or older increased 20-fold to 39.2%. Pretransplant diabetes prevalence rose 3.1-fold (12%–37%) and obesity 5.2-fold (6%–31%). Similar trends are reflected in SRTR data and are projected to worsen. McCullough et al4 modeled that declining end-stage renal disease mortality, combined with population-level shifts in age, obesity, and diabetes, will drive a 29%–68% growth in the total end-stage renal disease population by 2030, reaching up to 1.26 million Americans. The Cox regression confirms that donor age, recipient age, delayed graft function, pretransplant diabetes, and cardiovascular comorbidities are independently associated with inferior ACGS even after era stratification, a finding that is both expected and important, as it grounds the observed survival reversal in modifiable and measurable risk factors rather than unmeasured secular confounders. The most clinically consequential observation is the shift in cause of graft loss. Death with a functioning graft now accounts for >60% of all losses (75% including COVID-19), and infectious deaths nearly doubled from 21% to 45% (P < 0.01), persisting after COVID-19 exclusion (21% versus 35%, P = 0.007). Belgian and Finnish registry studies similarly document a transition from cardiovascular toward infectious causes of death across transplant eras.5,6 Meier-Kriesche et al7 first showed that older recipients face an exponentially increased risk of infectious death compared with waitlisted controls, a consequence of immunosenescence compounded by potent immunosuppression. The Manitoba data extend this principle >5 decades: median age at death rose from 54 to 65–66 y across eras, suggesting that a growing proportion of contemporary graft losses reflect the natural consequences of aging and competing comorbidity rather than therapeutic failure. Programs should be cautious about using ACGS as the sole benchmark of quality in an era when death with a functioning graft increasingly represents a life well lived with a working kidney. Two additional findings warrant attention. First, the association between Thymoglobulin induction and inferior ACGS (hazard ratio, 1.33; 95% confidence interval, 1.02-1.74) should be interpreted cautiously: the signal disappears in the death-censored model and is attenuated when primary nonfunction is included (hazard ratio, 1.23; 95% confidence interval, 0.95-1.59), pointing to confounding by indication rather than a causal effect. Thymoglobulin was disproportionately used in immunologically higher-risk recipients, a profile not fully captured by variables available across all eras. US registry analyses confirm that lower-intensity induction achieves equivalent graft outcomes in older, low-risk recipients, with potentially fewer infections.8 Second, Indigenous and African-Canadian recipients carry significantly elevated risks of allograft loss (HR 1.57 and 1.80, respectively). The sensitivity analysis incorporating HLA-DR/DQ alloimmune risk attenuates but does not eliminate the Indigenous signal, supporting both an immunological and a social-determinants explanation. With approximately 394 Indigenous recipients, this is likely the largest single-center Indigenous kidney transplant cohort reported in the literature, a data set of singular scientific and policy value that merits dedicated future investigation. Older recipients exhibit immunosenescence with lower acute rejection risk,9 yet their kidneys, often from similar aged donors, are more vulnerable to calcineurin inhibitor nephrotoxicity. Hence, calling for precision immunosuppression in an aging population is timely. The OPTIMIZE trial, a randomized comparison of reduced-exposure tacrolimus plus everolimus versus standard tacrolimus/mycophenolate in recipients aged 65 y or older, represents the prospective evidence needed to operationalize this approach.10 The Manitoba data show that each decade of donor age increase corresponds to a 6 mL/min decline in 1-y estimated glomerular filtration rate, a reduction that may itself amplify susceptibility to infection-related hospitalization. Calibrating immunosuppression intensity to immunological risk, donor quality, and recipient frailty, rather than applying a uniform protocol, is arguably the defining pharmacological challenge of contemporary transplantation. Limitations include single-center generalizability, the inability to adjust for HLA class II mismatch or frailty in the primary model, nonadjudicated cause-of-death attribution, and potential diagnostic drift in comorbidity ascertainment >5 decades. These caveats do not diminish what Wiebe et al2 have achieved. By demonstrating with directly observed data that the immunosuppression plateau of the post–tacrolimus era has been outpaced by the demographic tide of aging and comorbidity, they provide an empirical foundation for a fundamental reorientation of transplant medicine: from rejection prevention toward comprehensive, age-adapted risk management. Programs worldwide would benefit from similar long-term consecutive analyses. In their absence, the Manitoba experience stands as a clear reference point for what the modern transplant population demands of us.